Tolerance Bio, Inc.
PrivateLast Round
Early Stage
VC
Jun 3, 2026
Total Funding Raised
$20.2M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Tolerance Bio, Inc. operates in Healthcare & Life Sciences and is based in Philadelphia, Pennsylvania. Its latest recorded funding round was a Seed round in December 2024.
Tolerance Bio, Inc. is a biopharmaceutical company developing therapies focused on manipulating immune tolerance via the thymus to address various immune-mediated diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B2C
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tolerance Bio, Inc. Comparables
Compare Tolerance Bio, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Thymmune Therapeutics | 90% | |
| TECregen | 76% | |
| Sumitomo Pharma Co., Ltd. | 73% |
For institutional investors. Book with your work email.
Tolerance Bio, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Stage VC | Jun 3, 2026 | ||||
| Seed | Dec 19, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Tolerance Bio, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pacific 8 Ventures | Seed |
| Benjamin Franklin Technology Partners | Seed |
| Sessa Capital | Seed |
| BioAdvance Capital | Seed |
| Criteria Capital Risc | Seed |
| Columbus Venture Partners | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 3, 2026
$15.1M raised in an early stage VC round.
- Dec 19, 2024
$20M round led by Columbus Venture Partners.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 30, 2026
Tolerance Bio, Inc. is developing medicines targeting thymic biology, including TLB-33, to explore preserving thymic output and supporting immune function.
- is_developingSep 29, 2026
On Sep 30th '26, Tolerance Bio, Inc. said it is developing therapies to preserve and restore thymic function and plans to advance TLB-33 into Phase 2 clinical development.
- partners_withAug 20, 2026
On Aug 20th '26, Tolerance Bio, Inc. partners with NeoImmuneTech, Inc. under an exclusive license agreement to develop and commercialize efineptakin alfa, also known as NT-I7, for specific thymus-related indications in the Americas and Europe.
For institutional investors. Book with your work email.
Tolerance Bio, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Tolerance Bio, Inc.'s valuation, stock price, and market status.
Is Tolerance Bio, Inc. a public or private company?
Tolerance Bio, Inc. is a private company.
What is the current stock price of Tolerance Bio, Inc.?
Tolerance Bio, Inc. is a private company, so its shares have no public market price. Caplight tracks Tolerance Bio, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Tolerance Bio, Inc. worth (valuation)?
Valuation information for Tolerance Bio, Inc. is not publicly available.
Can I buy Tolerance Bio, Inc. stock?
Tolerance Bio, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Tolerance Bio, Inc.'s last funding round?
Tolerance Bio, Inc.'s most recent funding round was Early Stage VC on June 3, 2026.
Who are the main investors in Tolerance Bio, Inc.?
Key investors in Tolerance Bio, Inc. include Columbus Venture Partners.
Will Tolerance Bio, Inc. IPO soon?
No public IPO plans have been announced for Tolerance Bio, Inc..
How can I track Tolerance Bio, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Tolerance Bio, Inc.'s shares on secondary markets.